Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
Hydroxychloroquine use does not increase risk of heart failure in RA patients
Use of hydroxychloroquine (HCQ) does not contribute to the development of heart failure (HF) in patients with rheumatoid arthritis (RA), a study has shown.
Hydroxychloroquine use does not increase risk of heart failure in RA patients
15 Oct 2021
Climbing stairs boosts vascular function in patient with hypertension
Climbing stairs is a simple method of assessing physical activity in patients with hypertension and may lead to improved vascular function, a recent study has found.
Climbing stairs boosts vascular function in patient with hypertension
14 Oct 2021
Dapagliflozin improves symptoms, physical limitations in HFpEF
Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.
Dapagliflozin improves symptoms, physical limitations in HFpEF
13 Oct 2021
Cilostazol makes good in DAPT for recurrent stroke prevention in high-risk patients
Dual antiplatelet therapy (DAPT) with cilostazol performs better than either aspirin or clopidogrel alone at reducing the risk of recurrent stroke or vascular events without increasing the incidence of bleeding for patients with ischaemic stroke and intracranial arterial stenosis, according to the results of the CSPS.com* trial.
Cilostazol makes good in DAPT for recurrent stroke prevention in high-risk patients
13 Oct 2021
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
Adherence to a Mediterranean dietary pattern among polyvascular atherosclerotic disease (PAD) patients leads to improvements in inflammatory and metabolic status, which may potentially translate into better long-term cardiovascular outcomes, according to a study.
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
13 Oct 2021
Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS
Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.